CS/BSE/NSE/PR/2016-2017

December 8, 2016
To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,
Sub: Press Release

With reference to above subject, please find enclosed Press Release of our
company titled Suven to present at 9th CLINICAL TRIALS ON ALZHEIMER'S
DISEASE (CTAD) Conference held during December 8-10, 2016 at San Diego, USA
This is for your information and records
Thanking You,
Yours faithfully,
For Suven Life Sciences Limited
K. Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I C IN : L 2 41 1 0TG 1 98 9 P L C 00 9 71 3
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

News Release
Suven to Present at 9th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD)
Conference held during December 8-10, 2016 at San Diego, USA
HYDERABAD, INDIA (Dec 8, 2016) Suven Life Sciences is participating and presenting
positive Phase-1 clinical data of several advanced molecules from their portfolio of new
chemical entities (NCEs) at 9th CLINICAL TRIALS ON ALZHEIMER'S DISEASE
(CTAD) Conference held during December 8-10, 2016 at San Diego, USA.
Alzheimers disease is one of the most important health challenges facing aging
populations worldwide. The development of the next generation of Alzheimers disease
treatments is among the most important health needs worldwide, but presents huge
challenges.
The goal of 9th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference is to bring
together todays worldwide leaders in the treatment of Alzheimers disease to discuss
new results, candidate therapeutics, and methodological issues important to the
development of the next generation of Alzheimers disease treatments.
During CTAD- 2015 Suven lined up several face to face meetings with major Pharma and
Biotech companies to explore potential partnering and out licensing of the clinical
candidates SUVN-502, SUVN-G3031, SUVN-D4010 and SUVN-911.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and
commercializing novel pharmaceutical products, which are first in class or best in class CNS
therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2
initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and SUVND4010 for Alzheimers disease and Schizophrenia and a phase 1 ready SUVN-911 for Major
Depressive Disorder (MDD). In addition to that the Company has nine (9) internallydiscovered therapeutic drug candidates currently in pre-clinical stage of development
targeting conditions such as ADHD, dementia, depression, Huntingtons disease, Parkinsons
disease and pain.
For more information please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including
expectations and assumptions, contained in this news release may be forward-looking statements that
involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances might differ from the assumptions on
which such statements are based. Other important factors which could cause results to differ materially
including outsourcing trends, economic conditions, dependence on collaborative partnership programs,
retention of key personnel, technological advances and continued success in growth of sales that may make
our products/services offerings less competitive; Suven may not undertake to update any forward-looking
statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th FloorRoad No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I C IN : L 2 41 1 0TG 1 98 9 P L C 00 9 71 3
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com